<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681625</url>
  </required_header>
  <id_info>
    <org_study_id>09072020</org_study_id>
    <nct_id>NCT04681625</nct_id>
  </id_info>
  <brief_title>Evaluation of Silodosin and Pelvic Floor Muscle Training in Men With Benign Prostatic Hyperplasia and Overactive Bladder</brief_title>
  <acronym>SILODOSING</acronym>
  <official_title>Randomised Intervention Multicentre Study to Evaluate the Effect of Pelvic Floor Muscle Training in Men With BPH and OAB Treated With Silodosin - The SILODOSING Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Comenius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Comenius University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of pelvic floor muscle training in men with benign&#xD;
      prostatic hyperplasia and overactive bladder treated with Silodosin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised-intervention, parallel, multicentre study which will evaluate the&#xD;
      efficacy of pelvic floor muscle training in men with benign prostatic hyperplasia and&#xD;
      overactive bladder treated with silodosin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of voidings and intensity of urgencies during 24 hours using a micturition diary.</measure>
    <time_frame>over 12 weeks of treatment</time_frame>
    <description>The investigators will compare change in the number of voidings and the intensity of urgencies during 24 hours in the combined silodosin and pelvic floor muscle training to silodosin treatment alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lower urinary tract symptoms.</measure>
    <time_frame>over 12 weeks of treatment</time_frame>
    <description>To examine changes in the score of lower urinary tract symptoms (LUTS) by the International Prostate Symptom Score (IPSS) in the combined silodosin and pelvic floor muscle training to silodosin treatment alone. 0 = minimum score, 35 = maximum score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in incontinence quality of life .</measure>
    <time_frame>over 12 weeks of treatment</time_frame>
    <description>To examine change in incontinence quality of life by Overactive Bladder Questionnaire (OAB - q) in the combined silodosin and pelvic floor muscle training to silodosin treatment alone.&#xD;
0 = the worst to 100 = the best quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient global impression of improvement</measure>
    <time_frame>over 12 weeks of treatment</time_frame>
    <description>To examine changes in patient global impression of improvement in the combined silodosin and pelvic floor muscle training to silodosin treatment alone . 1 = much better. 7 = definitely worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events .</measure>
    <time_frame>over 12 weeks of treatment</time_frame>
    <description>To examine the incidence of adverse events in the combined silodosin and pelvic floor muscle training to silodosin treatment alone.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Standard silodosin treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peroral treatment with silodosin at a dose of 8 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard silodosin treatment with PFMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peroral treatment with silodosin at a dose of 8 mg daily Intervention: Behavioural: Pelvic floor muscle training (PFMT) with suppressive urgency technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pelvic floor muscle training (PFMT) with suppressive urgency technique</intervention_name>
    <description>Pelvic floor muscle training with suppressive urgency technique:&#xD;
Education about proper urination training in the period without pathological urgency.&#xD;
Education about conscious urgency suppression through PFMT - suppressive urgency technique.&#xD;
Education on the principle and effect of PFMT.&#xD;
Exercises of varying intensity of pelvic floor muscles in different positions.&#xD;
Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day.</description>
    <arm_group_label>Standard silodosin treatment</arm_group_label>
    <arm_group_label>Standard silodosin treatment with PFMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        • willing to provide written informed consent&#xD;
&#xD;
          -  men over 50 years with lower urinary tract symptoms and overactive bladder and benign&#xD;
             prostatic hyperplasia&#xD;
&#xD;
          -  persistence of overactive bladder despite 4 weeks of silodosin treatment&#xD;
&#xD;
          -  symptoms of overactive bladder (urinary frequency and urgency with or without urinary&#xD;
             incontinence) for ≥3 months prior to visit 1.&#xD;
&#xD;
          -  willing and able to complete the 3-day voiding diary and questionnaires&#xD;
&#xD;
          -  International Prostate Symptom Score (IPSS) score ≥8.&#xD;
&#xD;
          -  experience an average of 8 or more micturition's per day over the 3-day diary period.&#xD;
&#xD;
          -  experience an average of 2 episodes of urgency per day (grade 3 or 4) over the 3-diary&#xD;
             period&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  post-void residual volume (PVR) &gt;200 mL&#xD;
&#xD;
          -  evidence of Urinary Tract Infection and haematuria&#xD;
&#xD;
          -  use anticholinergics, beta 3 mimetics within 4 weeks prior to Visit 1 and during the&#xD;
             study&#xD;
&#xD;
          -  oncological diseases of the lower urinary tract and prostate&#xD;
&#xD;
          -  neurogenic bladder&#xD;
&#xD;
          -  urethral strictures and bladder neck stenosis&#xD;
&#xD;
          -  urolithiasis&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
          -  previous surgery of lower urinary tract&#xD;
&#xD;
          -  stress urinary incontinence&#xD;
&#xD;
          -  intermittent catheterisation&#xD;
&#xD;
          -  chronic urinary tract infection&#xD;
&#xD;
          -  previous botox treatment in the last 12 months&#xD;
&#xD;
          -  chronic electrostimulation treatment of OAB in the last 12 months&#xD;
&#xD;
          -  patient began or has changed a bladder training program or pelvic floor exercises less&#xD;
             than 90 days before 1 visit&#xD;
&#xD;
          -  cognitive deficits and dementia&#xD;
&#xD;
          -  man has participated in an interventional trial within 30 days prior to Visit 1&#xD;
&#xD;
          -  total daily urine production over 2500 mL according to voiding diary&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Men</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Svihra, Prof,MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Urology, Jessenius Faculty of Medicine, Comenius University Bratislava Slovak Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdalena Hagovska, Assoc.pr.PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, PJ Safarik University, Kosice, Slovak Republic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Svihra, Prof,MD,PhD</last_name>
    <phone>+421434133034</phone>
    <email>jan.svihra@uniba.sk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jan Svihra</name>
      <address>
        <city>Martin</city>
        <zip>03601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Svihra, prof</last_name>
      <phone>+421905369155</phone>
      <email>jan.svihra@uniba.sk</email>
    </contact>
    <contact_backup>
      <last_name>Jan Svihra, prof</last_name>
      <phone>+421434203444</phone>
      <email>svihra.jan@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign prostatic hyperplasia</keyword>
  <keyword>overactive bladder</keyword>
  <keyword>silodosin</keyword>
  <keyword>pelvic floor muscle training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

